Last updated: 2026-09-09 05:49:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tarsus Pharmaceuticals, Inc. (TARS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $87.19, with a market capitalization of $3.98B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $48.20 to $91.53. This page covers its latest market performance, valuation, price trends and company information.
$3.98B | |
$89.67 | |
$91.53 | |
$10.80 | |
$90.78 | |
1.58M | |
975.88K | |
-- | |
$91.53 | |
$48.20 | |
-- | |
-- |
Tarsus Pharmaceuticals, Inc. (TARS) last closed at $90.78 as of 2026-09-08 23:32:00, unchanged from the previous close of $90.78.
During the latest regular trading session, TARS traded between $10.80 and $91.53, with a volume of 1.58M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Tarsus Pharmaceuticals, Inc. (TARS) moved from $71.92 to $87.19, representing a gain of 21.23% ($15.27).
The stock traded between $69.47 and $91.53 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.00 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 90.0%
TARS is currently trading at $87.19, placing it 90.0% of the way from its 52-week low of $48.20 to its 52-week high of $91.53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 370 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tarsus Pharmaceuticals, Inc. (TARS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.